Matching articles for "page 81"

Generic Drugs Revisited

   
The Medical Letter on Drugs and Therapeutics • October 19, 2009;  (Issue 1323)
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence...
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported. Is that still true? New data have become available for some drugs.
Med Lett Drugs Ther. 2009 Oct 19;51(1323):81-2 | Show Full IntroductionHide Full Introduction

Certolizumab (Cimzia) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • October 20, 2008;  (Issue 1297)
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is...
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81-2 | Show Full IntroductionHide Full Introduction

In Brief: Melamine

   
The Medical Letter on Drugs and Therapeutics • October 20, 2008;  (Issue 1297)
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1

Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware, whiteboards and laminate flooring.1 Because of its nitrogen content, melamine has been illegally added to products such as milk, wheat gluten and rice protein to factitiously boost the apparent protein content; common assays for protein content do not distinguish between amino-acid nitrogen and non-protein nitrogen.

Melamine itself is relatively nontoxic; the FDA has established, based on an extrapolation from studies in rats, a tolerable daily intake of 0.63 mg/kg/day.1 However, the combination of melamine with cyanuric acid (a water disinfectant and/or impurity associated with melamine production that itself is also nontoxic) results in the formation of insoluble crystals that precipitate in renal tubules following ingestion and may cause acute renal failure.2-4 Infants may be especially sensitive to this mechanism of toxicity.

Treatment of humans or animals poisoned with these compounds is largely supportive. Hemodialysis may be indicated, depending on the degree of renal failure. Whether hemodialysis removes melamine or related compounds is unknown.

1. U.S. Food and Drug Administration. Interim safety and risk accessment of melamine and its analogues in food for humans. October 3, 2008. Available at www.cfsan.fda. gov/~dms/melamra3.html. Accessed October 14, 2008.
2. CA Brown et al. Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007. J Vet Diagn Invest 2007;19:525.
3. RL Dobson et al. Identification and characterization of toxicity of contaminants in pet food leading to an outbreak of renal toxicity in cats and dogs. Toxicol Sci 2008; 106:251.
4. World Health Organization. Melamine and cyanuric acid: toxicity, preliminary risk assessment and guidance on levels in food. September 25, 2008. Available at www.who.int/foodsafety/fs_management/Melamine.pdf. Accessed October 14, 2008.

Download U.S. English
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2007-2008

   
The Medical Letter on Drugs and Therapeutics • October 8, 2007;  (Issue 1271)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications....
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Med Lett Drugs Ther. 2007 Oct 8;49(1271):81-3 | Show Full IntroductionHide Full Introduction

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • September 1, 2007;  (Issue 61)
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric...
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases.
Treat Guidel Med Lett. 2007 Sep;5(61):81-9 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2006-2007

   
The Medical Letter on Drugs and Therapeutics • October 9, 2006;  (Issue 1245)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Med Lett Drugs Ther. 2006 Oct 9;48(1245):81-3 | Show Full IntroductionHide Full Introduction